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With the rapid growth of publicly available high-throughput tran-
scriptomic data, there is increasing recognition that large sets of
such data can be mined to better understand disease states and
mechanisms. Prior gene expression analyses, both large and small,
have been dichotomous in nature, in which phenotypes are com-
pared using clearly defined controls. Such approaches may require
arbitrary decisions about what are considered “normal” pheno-
types, and what each phenotype should be compared to. Instead,
we adopt a holistic approach in which we characterize phenotypes
in the context of a myriad of tissues and diseases. We introduce
scalable methods that associate expression patterns to phenotypes
in order both to assign phenotype labels to new expression sam-
ples and to select phenotypically meaningful gene signatures. By
using a nonparametric statistical approach, we identify signatures
that are more precise than those from existing approaches and
accurately reveal biological processes that are hidden in case vs.
control studies. Employing a comprehensive perspective on expres-
sion, we show how metastasized tumor samples localize in the
vicinity of the primary site counterparts and are overenriched
for those phenotype labels. We find that our approach provides
insights into the biological processes that underlie differences be-
tween tissues and diseases beyond those identified by traditional
differential expression analyses. Finally, we provide an online
resource (http://concordia.csail.mit.edu) for mapping users’ gene
expression samples onto the expression landscape of tissue and
disease.
large-scale analysis ∣ personalized medicine ∣ phenotype classification
Although gene expression microarrays have been a standard,widely utilized biological assay for many years, we still lack a
comprehensive understanding of the transcriptional relationships
between various tissues and disease states. Even with the hun-
dreds of thousands of expression array datasets available through
public repositories such as National Center for Biotechnology
Information’s (NCBI’s) Gene Expression Omnibus (1) (GEO),
the lack of standardized nomenclature and annotation methods
has made large-scale, multiphenotype analyses difficult. Thus, ex-
pression analyses have typically used the decade-old approach of
comparing expression levels across two states (e.g., case vs. con-
trol) or a limited number of phenotype classes (2–4). Even recent
large-scale gene expression investigations, whether they have at-
tempted to elucidate phenotypic signals (5–7) or applied those
signals for downstream analyses such as drug repurposing (8, 9),
involve comparisons between two states or classes.
Comparative analyses, where transcriptional differences are
directly measured between two phenotypes, inherently impose
subjective decisions about what constitutes an appropriate con-
trol population. Importantly, such analyses are fundamentally
limited in scope and cannot differentiate between biological pro-
cesses that are unique to a particular phenotype or part of a larger
process that is common to multiple phenotypes (e.g., a generic
“cancer pathway”). Moreover, the results of such comparative
analyses can be limited in generalizability as they make assump-
tions about the phenotypes being compared (10). Alternatively, in
a data-rich environment, we can take a holistic view of gene ex-
pression analyses.
In this paper we introduce scalable and robust statistical
approaches that leverage the full expression space of a large di-
verse set of tissue and disease phenotypes to accurately perform
and glean biological insights from both sample- and gene-centric
analyses. By viewing a given phenotype in the context of this com-
prehensive transcriptomic landscape, we circumvent the need for
predefined control groups and presupposed relationships be-
tween phenotypes (Fig. 1A). We devise, implement and validate
the accuracy of an enrichment statistic that provides detailed
phenotypic information for new samples when they are mapped
onto and compared with the transcriptomic landscape (http://
concordia.csail.mit.edu).
Our perspective on interpreting gene expression space helps
uncover phenotype-specific marker genes beyond those discov-
ered by traditional dichotomous views of gene expression. We in-
troduce a method based on a finite impulse response filter (11)
used in signal processing to reveal, for instance, marker genes in-
volved in carbohydrate and lipid metabolism as key processes in
breast cancer. Such findings are in contrast to those of traditional
over- and underexpression based analyses, which focus on generic
cancer processes not specific to breast cancer such as cell cycle
and cell adhesion (12). Capitalizing on the hierarchical nature
of the phenotypic labels associated with our samples, we also
demonstrate that genes previously linked to specific types of car-
cinomas may actually be part of a broader “carcinoma” process.
Finally, we illustrate how metastasized tumor samples are tran-
scriptomically more proximal to other cancer samples from their
respective primary sites, as opposed to cancerous tissue from the
metastasis sites from which the samples were resected.
Results
Making Sense of the Transcriptomic Landscape.As an initial step to-
wards a holistic approach to gene expression analysis, we must
make sense of the substructure of the global transcriptomic land-
scape. We first constructed a curated gene expression database of
3,030 diverse samples (from 192 series) obtained from NCBI’s
GEO (1). These samples were annotated with their phenotypes
(tissue of origin, disease state, etc.) using the anatomical and
disease concepts in a custom subset of the Unified Medical Lan-
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guage System (13) (UMLS) concept ontology via both natural
language processing and manual validation (Methods).
Although visualizing the full transcriptomic landscape encom-
passing all genes is not feasible, the first two principal compo-
nents (PCs) of the expression level of 20,252 genes across the
database provide a representation of the phenotypic relationships
that captures roughly 20% of the variance in the data (Methods).
Although others have suggested that the primary factors driving
the organization of the global transcriptomic landscape can lar-
gely be attributed to hematopoietic and malignant programming
(14), we alternatively see the cell and tissue-specific signatures of
blood, brain, and soft tissue are dominant (Fig. 1B). Furthermore,
these PCs recapitulate the phenotypic relationships captured in a
tissue network (Supporting Information) derived from a de novo
tissue correlation analysis (Methods). Indeed, when analyzing the
tissue-specific characteristics of these clusters, we observe the
overexpression of fibrillar and epithelial genes such as COL3A1,
COL6A3, KRT19, KRT14, and CADH1 in the soft-tissue cluster
and neural genes such as GFAP, APLP1, GRIA2, PLP1, and
SLC1A2 in the brain cluster. Gene ontology (GO) enrichment
analysis of the top 250 tissue-specific genes for each cluster
further points to overenrichment for terms related to each of
the three tissue types (Supporting Information). Several reports
have stated that data from different datasets are not comparable
as the dataset signal is dominant (10, 15); however, we find that
the tissue signal is dominant in this macroscopic view (Supporting
Information).
By additionally performing principal component analysis on
soft-tissue samples (all noncancerous samples that are also not
blood or brain), it becomes apparent that phenotypic grouping
occurs on multiple levels of phenotypic granularity. Not only are
individual tissue samples in confined regions, they are also orga-
nized by functionality. Tissues sensitive to reproductive hormones
(ovary, uterus, myometrium, endometrium, prostate, penis, and
breast) group together to form a distinct subregion in the smooth
landscape (Fig. 1C). Juxtaposed to them are primarily gastroin-
testinal tract samples from tissues such as colon, stomach, intes-
tine, liver, and esophagus.
Concordia: Phenotypic Concept Enrichment. Although correlation
analyses and the visual representation of the transcriptomic land-
scape provide insight into the broad relationships between var-
ious phenotypes, our ability to harness these expression signals
to map previously unseen samples into a database of expression
samples is compelling. Beginning with our customized UMLS
concept annotation of the 3,030 samples, we restricted the set
of UMLS concepts to the 1,489 anatomy and disease concepts
that mapped to at least three expression samples (Supporting
Information). We developed a sample-centric method based on
the Kolmogorov–Smirnov statistic to label new samples with
UMLS concepts that are overrepresented in their local expres-
sion neighborhoods (Methods). No hard boundaries are drawn
when a new input sample is labeled, but rather the concepts per-
tinent to the transcriptomic neighborhood for the input sample
are reported. Importantly, as it is often difficult to define an
appropriate control, this approach has the advantage that it
does not require case-control type input but, rather, just a single
microarray sample. To illustrate its function, we provide a web
resource, Concordia (http://concordia.csail.mit.edu), that allows
users to submit their own microarray samples performed on
the popular Affymetrix HG-U133 Plus 2.0 array and obtain their
overenriched tissue and disease concepts.
We performed leave-one-sample-out cross-validation to vali-
date the accuracy of our method for assigning an unknown
sample to the correct phenotype. The receiver operating charac-
teristic (ROC) curve was computed for each of the 1,489 UMLS
concepts, and the standard measure of area under the curve
(AUC) that summarizes both the true-positive and false-positive
rates was used as a measure of accuracy. We see an average
accuracy of 92.8% after restricting the set of UMLS concepts
to the 1,209 that have samples from two or more expression series
in GEO to ensure that a diverse set of data is used. Even when we
restrict the concepts to the 450 that have at least 50 samples
originating from at least five different data series, the average
accuracy is approximately 89.8%. Table 1 contains the perfor-
mance of a selection of UMLS concepts, along with the number
of samples and series that were associated with that concept.
Unsurprisingly, “broader” concepts have poorer performance
compared to the more specific concepts, as the former encompass
a much more diverse expression signal. The performance values
are in Supporting Information, and the ROC curves are available
on the web site. Note that many of these concepts are similar and
have samples in common; consequently, many of the concepts
have similarly high (low) AUC values.
Fig. 1. Comprehensive view of gene expression.
(A) A comprehensive perspective on expression ana-
lysis enables the elucidation of biological signals that
are thematically coherent but provide an alternative
view to traditional dichotomous approaches. For
example, the gene-signature for “breast cancer” is
enriched for breast-specific development and carbo-
hydrate and lipid metabolism in our comprehensive
approach, as opposed to being dominated by a more
general “cancer” signal. (B) The gene expression
landscape, as represented by the first two principal
components of the expression values of 20,252 genes
from 3,030 microarray samples separates into three
distinct clusters: blood, brain, and soft tissue. The
shading of the regions corresponds to the amount
of data located in that particular region of the land-
scape such that the darker the color, the more data
exists at that location. Interestingly, the area where
the soft tissue intersects the blood tissue corresponds
to bone marrow samples, and where it intersects the
brain tissue, mostly corresponds to spinal cord tissue
samples. (C) There is a clear separation of reproduc-
tive and gastrointestinal tissue samples in the soft-
tissue cluster.
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We see a significant increase in accuracy as more data is added
to the underlying database. For example, when half of the sam-
ples associated with each concept are removed, the global perfor-
mance is a mere 44%, compared to the aforementioned 93%
(Supporting Information). This implies that the phenotypic signal
becomes stronger and the power of this type of macroscopic
analysis increases with the amount of underlying data. As our
approach employs a nonparametric enrichment statistic that only
requires the concept annotation of the samples in the original
gene expression database, it can be updated in real-time without
having to “retrain” the database. A system such as this could thus
be deployed in a research or clinical setting where new samples
are continually being added and analyzed, with minimal altera-
tion of normal protocols.
Primed with the 3,030 labeled samples, we applied Concordia
to 15,904 other GEO samples performed on the Affymetrix
HG-U133 Plus 2.0 array. These enrichment scores represent the
expression patterns as characterized by the 1,489 anatomy and
disease-related concepts and can be used as an additional source
of biological information when performing future large-scale
gene expression analyses (Supporting Information).
Phenotypic-Specific Marker Genes.We developed a method to iden-
tify marker genes that characterize a specific phenotype in the
context of broad transcriptomic landscapes, and not in the con-
text of dichotomous classes. Instead of defining a marker gene as
one that is over- or underexpressed in a case vs. control study
using methods akin to t-tests, we define a marker gene as a gene
that has a “localized” expression signature for a phenotype; i.e.,
how grouped together all of the samples are corresponding to
that phenotype for that gene. If all of the samples for a phenotype
have a very similar expression level (all high, all low, etc.), the
gene may be considered a marker gene for that phenotype. We
employ a finite impulse response filter (FIRF) (11) on each
gene’s expression values across the entire database of 3,030
diverse expression samples to quantify the degree of expression
level localization for a given phenotype. To generate the set of
genes most relevant to a phenotype, we use the marker gene
localization scores to rank all genes and then we identify the
cutoff for the number of genes to include by balancing the set’s
ability to accurately classify samples of its own phenotype while
minimizing the presence of non-phenotype-specific signal (Meth-
ods). Not only does this method sidestep the requirement of
defining appropriate “control” phenotype(s), it also facilitates the
identification of thematically coherent gene signatures that reveal
very different aspects of biology from traditional ones.
As an example, we derived the breast cancer gene set from a
landscape of 673 samples representing 17 different cancerous
tissues. The 74 genes that comprise this set are functionally en-
riched for processes related to breast-specific development, and
carbohydrate and lipid metabolism (Supporting Information).
These pathways, revealed through gene expression, are consistent
with independent clinical and genetic data suggesting an impor-
tant role for carbohydrate and lipid metabolism in breast cancer.
For example, women with type 2 diabetes may have higher sus-
ceptibility to breast cancer (16). Three genes specifically impli-
cated in this analysis, ENPP1, ADIPOQ, and PPARA, are of
particular interest. ADIPOQ is expressed in adipose tissue exclu-
sively. Variants in the ADIPOQ gene and protein levels are im-
plicated in prostate cancer (17) and breast cancer (18). Similarly,
ENPP1 levels have been correlated to progression-free survival
in tamoxifen-treated patients with breast cancer (19). PPARA
is one of a family of nuclear transcription factors that has been
found to stimulate both adipocyte (fat cell) differentiation and
fatty acid oxidation (20). Moreover, the PPARA signaling path-
way has been implicated in breast cancer progression (21), and
in a case-control study a polymorphism of PPARA was identified
to be associated with a twofold increase in breast cancer (22).
Notably missing from this list of enriched pathways are pro-
cesses commonly associated with cancer, such as cell–cycle and
cell–adhesion (12). We can recreate this conventional perspective
by selecting the set of candidate marker genes using a traditional
permutation t-test-based method (Methods). This reveals enrich-
ment for processes that are associated with cancer in general, but
not specific to breast cancer, such as “cellular response to tumor
necrosis factor,” “induction of apoptosis,” and other tumor-
related processes (Supporting Information). Furthermore, accord-
ing to the permutation t-test method, PPARA is less significant
than nearly 17% of the other genes (ADIPOQ is in the top
2% and ENPP1 is in the top 0.5%). In comparison, using the
FIRF, the tumor-necrosis-related genes, such as RIPK1, TRADD,
and TNFRSF25, do not appear until, respectively, 18%, 54%, and
97% of the other more breast-cancer-specific genes appear first.
To ascertain the “cancer” gene set using our FIRF-based meth-
od, however, we expanded the landscape of data to include not
only 17 cancers but also 2,187 samples across 30 noncancerous
tissue types. By comparing all cancers against all noncancers,
we unsurprisingly then find that the most significant genes are
functionally enriched for processes that are typically associated
with tumors: “cell division,” “cell cycle,” and “DNA repair,” to
name but a few. Taken together, landscape-based gene signature
discovery can recapitulate canonical cancer pathways but also can
identify a complementary set of gene signatures with distinct
biological implications.
Specificity of Marker Genes. It has been suggested that the so-called
“incidentalome” of incidental findings is a threat that has yet
to be addressed in either biological or clinical settings (23). The
consequences of noncomprehensive views of biomarkers, such as
prostate-specific antigen, continue to cause needless harm and
costs (24). By performing analyses in the context of a large
database of biological samples, however, we see that many genes
are not specific to a single disease.
To illustrate this, we took the 459 carcinoma samples in our
database and computed the “carcinoma” marker gene localiza-
tion scores by comparing them to the 270 other tumor samples.
As the UMLS concepts are in a structured ontology, we com-
puted the marker gene scores for the 13 concepts subordinate
to “carcinoma” (e.g., “adenocarcinoma,” “adenosquamous carci-
noma”) for which we had at least three expression samples. From
the list of genes sorted by their carcinoma marker gene score
p-value, we removed all genes that had a better p-value in any
of the 13 subordinate concepts. This yielded a list of 5,805 genes
that had better p-values at the more general concept “carcinoma”
than at any of the more specific subordinate carcinoma types.
Functional enrichment analyses of the top 10, 20, 50, 100, and
150 genes in this list reveals processes such as “regulation of cell
adhesion,” “response to growth factors,” and other morphogen-
esis and development terms. Furthermore, within the sorted list
of carcinoma genes, we see genes previously implicated in carci-
Table 1. Concordia cross-validation performance on selected
UMLS concepts
Concept AUC No. series No. samples
Malignant neoplasms 0.82 74 855
Malignant neoplasm of breast 0.97 9 69
Malignant neoplasm of ovary 0.99 4 51
Malignant neoplasm of lung 0.97 4 98
Leukemia 0.99 13 151
Soft tissue 0.69 98 1,513
Breast 0.93 13 195
Ovary 0.95 8 103
Lung 0.95 9 131
Inflammatory disorder 0.79 13 91
Rheumatoid arthritis 0.93 7 31
Inflammatory bowel diseases 0.99 2 24
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nomas such as COL1A1 (25, 26) and ELF3 (27) in the top five. As
such, these genes that have previously been implicated in parti-
cular types of carcinomas may instead be part of a larger carci-
noma process, rather than specific to breast or colorectal cancer.
This sort of quantification of phenotype specificity is of course
relevant to the diagnostic accuracy of putative biomarkers and
for developing suitably broad-spectrum or targeted therapeutics.
As such, we computed the gene–phenotype expression localiza-
tion scores for all 20,252 genes and 1,489 concepts (Supporting
Information).
Tissue-Specific Signal of Tumor Metastases. The clinical problem
of distinguishing whether a cancerous lesion represents a primary
tumor, or a metastasis from a distant malignancy, presents a
test case for our ability to localize a sample to the appropriate
phenotypic group within the transcriptomic landscape. By com-
bining the aforementioned sample-and gene-centric methods,
we are able to map new tumor metastasis tissue samples onto the
expression landscape, providing an unbiased measure of their
phenotypic predisposition based on gene expression. It is com-
monly known by pathologists that tumor metastasis tissue biop-
sies viewed “under the microscope” resemble the tissue of the
primary site rather than that of the tissue in the metastasized
location. Nevertheless, the proper identification of the primary
site of a metastasis can be critical in determining the appropriate
clinical treatment plan (28). Indeed, we find that metastatic tissue
samples localize in the vicinity of their tissue of origin in the tran-
scriptomic landscape (Fig. 2), even without the use of specially
tuned primary site detection methods (28, 29).
For instance, in an analysis of 29 metastasized breast cancer
samples resected from lung, brain, and bone (GSE14107), the
metastases more closely resemble breast tissue than their biopsy
locations (Fig. 2A). Overenriched UMLS concepts from Concor-
dia for the metastasized samples include “white adipose tissue,”
“subcutaneous fat,” “subcutaneous tissue,” “lactiferous duct,”
“mammary lobe,” and “glandular structure of breast.” When we
restrict the analysis to use only the 164 genes in the breast gene
set identified using our aforementioned FIRF-based method,
we observe that these metastasized breast samples lie within the
context of other primary breast cancer samples in the database,
which in turn are juxtaposed to normal breast tissue (Fig. 2B).
Similarly, 15 of the 17 metastasized colorectal cancer samples
that were removed from liver (GSE10961) were all labeled with
“rectum and sigmoid colon,” “colonic diseases, functional,” and
“colon carcinoma” with a false-positive rate (FPR) below 0.05;
the other two samples had FPRs of 0.06 for “colon carcinoma.”
The top UMLS concepts for other metastatic samples obtained
from GEO are in Supporting Information.
Interestingly, the mislabeled metastases provide an unbiased
measure of the degree of overlap between the biological signals
of related tissues. This is particularly evident within the soft-tissue
cluster (Fig. 1B, Lower, Left), in which the tissue-specific signal
can be dwarfed by the larger variances caused by the blood and
brain tissue samples. Although the use of supervised learning
approaches could mitigate these issues (29), they minimize the
significant biological overlap of some of these samples, which
may have implications for therapeutic selection (30). For exam-
ple, due to the proximity of breast and ovarian tissue samples in
the global transcriptomic landscape, we had difficulty distinguish-
ing between breast metastases in the ovary and primary ovarian
carcinoma (GSE20565).
Discussion
With the ever-growing amounts of transcriptomic data, it has
become not only possible but also imperative to embrace the full
transcriptomic continuum of tissue and disease. Employing a
comprehensive, non case- vs.-control approach and making use
of the multidimensional nature of gene expression data, we
capture biological processes that are typically overshadowed in
traditional analyses. Furthermore, we are able to recapitulate
the biologically and medically relevant concepts relating to a
new expression sample through Concordia. Indeed, as the power
of this macroscopic analysis increases with the amount of data,
this approach has the potential to more fully leverage large da-
tabases with biological data and to benefit further as more data
are added. Although we have presented our sample-and gene-
centric methods utilizing medically relevant concepts and gene
expression data, the data-driven nature of these methods implies
that by changing the scope or domain of the labels and/or the
underlying quantitative data, they can be applied to analyses
in different contexts with relative ease. For instance, it is not
far fetched to imagine using these methods to create a transcrip-
tomic landscape based on RNAseq expression data (31) anno-
tated with concepts from RxNorm, a clinical drug vocabulary.
As suggested by some (32), systematic application of molecular
pathology measurements will allow a shifting of the convention-
ally employed diagnostic classification boundaries to include
Fig. 2. Sample- and gene-centric expression analyses show that metasta-
sized samples more closely resemble their primary sites than their biopsy
site. Legend applies to both plots. (A) Breast tumors that metastasized to
the lung, brain, and bone (GSE14107) still appear to be more closely related
to other breast samples (red shaded region) than to their metastasis sites
when placed in the transcriptomic landscape of 3,030 other expression sam-
ples. (B) Recomputing the PCs using only the 164 genes of the breast gene
set, as opposed to all 20,252 genes, recapitulates the proximity of the metas-
tasized breast cancer samples to breast tissue samples (orange shaded re-
gion), and shows that they lie within the confines of the other breast
cancer samples in the database.
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intermediate pathotypes that cross the boundaries of the conven-
tional medical classifications. These intermediate pathotypes are
more closely coupled to the actual underlying pathology, thus
revealing not only shared pathology but also opportunities for
development of shared treatment (30, 33). It may be the case
that the expression signatures of diseases provide clues to a dis-
ease network (34) other than what classical medical knowledge
dictates, thus providing insights to previously unknown disease
relationships.
It has been proposed that the future of personalized medicine,
and the proper application of genomic and genetic data, requires
an understanding of both who the patient is and the character-
istics of the subpopulation to which the patient belongs (35).
Clinical applications of our approach, together with other genet-
ic, environmental, and phenotypic information, could more accu-
rately and consistently annotate clinical samples and provide an
impartial view of the landscape of clinico-pathological classifica-
tion. As we employ an enrichment statistic that only requires the
usual standard of care in the labeling of samples, this system
could be deployed in a clinical setting with minimal alteration
of normal procedures. By shifting away from a dichotomous view
and employing the global transcriptomic landscape, we hope to
address one of the key requirements of personalized medicine
and begin to answer one of its fundamental questions, “what
other samples am I most similar to so that the most effective
treatment can be administered?”
Methods
Normalizing the gene expression samples. Our database is comprised of 3,030
gene expression samples belonging to 192 series performed on the Affyme-
trix HG-U133 Plus 2.0 arrays that were obtained from NCBI’s GEO (1). The
original CEL files were downloaded from GEO and Microarray Suite (MAS)
5.0 normalized. Subsequently all probe-specific values were converted to
gene-specific values using a trimmed mean. For the gene selection proce-
dure, we log-normalized all of the expression values to be between −1
and 1 to ensure a normal distribution. For all of the other analyses, the
expression values were additionally rank normalized.
UMLS Annotation. We follow the lead of Butte, et al. (36) and extracted the
title, description, and source fields from each of the 3,030 expression samples
and annotated them using the Java implementation of the National Library
of Medicine’s (NLM) MetaMap program, MMTx (37). A custom UMLS (13)
thesaurus containing concepts from the UMLS, Medical Subject Heading,
and Systematized Nomenclature of Medicine ontologies was generated
using NLM’s MetaMorphosys program. The automated annotations were
manually verified and 672 UMLS concepts were kept. As these concepts only
represented the most detailed level of annotation, they were mapped up the
ontology such that a sample labeled with a specific concept also received
labels corresponding to all of its ancestor concepts. Due to the domain of
the data, we filtered the concepts to only those that are descendants of
either “disease” or “anatomy,” resulting in 1,489 concepts.
Making Sense of the Transcriptomic Landscape. The transcriptomic landscape
visualization is the first two PCs of the PC projection of the 3,030 centered
and scaled gene expression samples. The phenotypic clusters portrayed by
shaded regions were created by iteratively using the convex hull function
(chull) in the R statistical language package. We performed the hierarchic
analysis of the landscape by taking the 1,065 phenotypically normal samples
in the soft-tissue cluster and recalculating the PCs. The convex hulls for the
gastrointestinal and reproductive clusters were computed in the aforemen-
tioned fashion.
The tissue similarity network was generated by computing correlations
of a representative sample of a tissue type to all other representatives of
the other tissues. The representative was chosen to be the sample that
was closest to the centroid in the set of samples for that phenotype. To con-
tend with sampling bias, the correlations were computed 100 times, the cen-
troid for each phenotype having been chosen from a random 75% subset of
the samples for that phenotype. The network was then created based on the
tissue–tissue relationships with an average correlation greater than 0.8 across
all 100 subsampling runs. The colors of the nodes denote the general tissue
class (blood, brain, gastrointestinal, reproductive, and other).
Our online resource also provides a visualization of where an input sample
lies in the transcriptomic landscape. An input sample’s coordinates are com-
puted by centering and scaling its expression values by constants learned
from the database and then applying the loadings from the first two PCs.
Picking Blood, Brain, and Soft Tissue-Specific Genes. Tissue-specific genes were
selected by performing permutation t-tests comparing, for example, the
log-normalized expression values for the blood samples for a given gene
to the log-normalized expression values of the samples associated with brain
and soft tissue. Each permutation run consisted of computing the t statistic
for the actual labeling of the samples and comparing it to the t statistics
produced when the labels were randomly permuted 200 times while keeping
the sample size distribution constant. To counter the potential influence of
sampling bias, this entire procedure was performed 100 times, each time
using only a random 75% of the data for each tissue type. Genes with a false
discovery rate corrected p-value of 0.05 or lower in all 100 runs were deemed
significant. As there were genes with identical p-values, the genes were
then sorted such that a gene with a larger difference in means between
the phenotypes was ordered before those with a smaller difference. GO
enrichment was performed on the top 50, 100, and 250 genes for each tissue
type using FuncAssociate 2 (38). We report only the GO terms that had a
resampling-based p-value less than 0.05.
Computing Phenotype-Specific Gene Signatures. To determine the level of
localization of the expression intensities for a given gene, we employed a
FIRF (11). For each gene g, phenotype p pair, we sort all of the expression
samples by their expression intensities for g. Using a “sliding window” of size
equal to the number of samples corresponding to p, we compute the fraction
of samples in that window that are associated with p. The value is 1 if all
samples in the window are associated with p and 0 if none of them are. This
window is iteratively moved across the sorted list of samples to obtain a value
for all positions. The marker gene score for a particular gene–phenotype pair
is the maximum value that is achieved in any of the windows. A p-value is
computed for each score using a binomial distribution.
To determine the appropriate cutoff for the number of genes to include in
the gene set for phenotype p, the genes are first sorted according to their
marker gene score from highest to lowest. We then iteratively examine the
quality of the top n genes, balancing their positive predictive capability with
the amount of additional noise. Starting with the first two highest scoring
genes, we iteratively remove each sample s and compute its correlation to
all other samples using only those two genes. We generate an ROC curve
for s and use the AUC as a summary statistic. The ROC curve is generated
by sorting all samples by their correlation to s and incrementing the true-
positive count when that sample is associated with p and incrementing
the false-positive count when that sample is not associated with p. Once
all AUCs are computed for two genes, we add the next highest scoring gene
and recompute all AUC values. We define the mean “hit” AUC as the average
AUC obtained by all samples associated with p, and the mean “miss” AUC
as the average AUC of all samples not associated with p. By taking the ratio
of the mean hit AUC and mean miss AUC at each number of genes n, we
determine the relevant set of genes as all genes in the sorted list up until
the number of genes that maximizes this ratio.
To compare the performance of the FIRF to the traditional over- and un-
derexpression-based analyses relying on differences in the mean expression
levels in the phenotypes being studied, we performed a t-test for each gene
and computed the empirical p-value based on 1,000 random permutations of
the phenotype labels. As many of the p-values were 0 (or the same), we
sorted the list of genes by the z score of the actual t statistic as compared
to the 1,000 t statistics generated by the random permutations. GO enrich-
ment was then performed using the Bioconductor GOstats (39) library in R.
Enrichment Score Calculation. We use the database of gene expression sam-
ples to assess overenrichment for particular disease- and tissue-specific
signals. Given a new expression profile, for each concept represented in the
database, we calculate a statistic that measures the strength of association
between the sample and concept, as implied by its similarity to the labeled
database samples.
The statistic is calculated as follows. First, the database consisting of n
curated expression samples fs1; s2; s3;…; sng is sorted (in decreasing order)
according to each observation’s Spearman correlation, ρ, with the new
profile. Let s1 0 ; s2 0 ; s3 0 ; ::; sn 0 represent the samples ordered according to
their correlation coefficients ρs1 0 ; ρs2 0 ; ρs3 0 ;…; ρsn 0 . For a given concept c in
the set C, the set of all UMLS concepts in our database, let Sc be the
set of all database samples associated with the concept. That is,
Sc ¼ fsi jsi is associated with cg. We define an ordered list of xi values:
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xi ¼

1þ ρ 0si
2

∕

∑
s 0j ∈Sc
1þ ρ 0sj
2

when sample si 0 is associated with concept c, and
xi ¼ −1∕ðn − jScjÞ
for all other samples that are not associated with concept c. Intuitively, when
si is associated with the concept in question, the xi value corresponds to the
fraction of total correlation between the new sample and all database sam-
ples associated with the concept. All of the xi values for the concept “hits”
sum to 1, and all of the xi values for the concept “misses” sum to −1.
Then we compute a running sum of xi across all n database samples and
take the maximum value achieved by this running sum as our enrichment
score (ES) for the concept in question:
Enrichment Scorec ¼ max
1≤j≤n ∑
1≤i≤j
xi
This sum across all n samples is zero. The concepts where there is strong
positive deviation from 0 are the concepts whose associated samples are
more highly correlated with the new profile than those samples that are
not associated with the concept.
Quantifying Performance. To quantify the ability of the method to recover
UMLS concepts based on an input expression profile, we generate an ROC
curve and calculate the AUC as a summary statistic for each concept repre-
sented in the database. To compute the ROC curve for each concept c in the
database, we iteratively leave out each sample s and compute s’s enrichment
score for c using the remaining database samples. We compute the running
true-positive (TP) and false-positive (FP) counts by walking down the list of
samples sorted by their enrichment score for c. The TP is incremented if the
ith sample in the list is actually labeled with concept c. If the sample is not
labeled with concept c, the FP is incremented. The true-positive results (TPRs)
and FPRs are obtained by dividing TP and FP, respectively, by the number of
known positives and negatives at each position i. By plotting the TPR vs. FPR
we obtain the ROC curve. The larger the area under the ROC curve (AUC), the
greater the gene expression signal for that concept as the samples with the
highest enrichment scores for the concept were truly labeled with that
concept.
When using this method to label a new sample, we compute its ES (w.r.t.
the entire database) for each concept. We then report the system’s estimated
FPR for each concept at the sample’s observed concept-specific enrichment
score. These FPR values are derived from the running statistics used to gen-
erate the ROC plots: Look up the new sample’s score position in the list of
sorted scores and report the FPR at that position (if there is not an exact
match, report the next-worst FPR).
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